TheraRadar
← Back
Data updated: Jun 28, 2026

AIR LIQUIDE HEALTHCARE AMERICA CORP

Pharma
Pharmaceuticals

AIR LIQUIDE HEALTHCARE AMERICA CORP is a pharmaceutical company with 1 FDA-approved products.

2013
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

AIR LIQUIDE HEALTHCARE AMERICA CORP's Key Drugs

AIR LIQUIDE HEALTHCARE AMERICA CORP's core commercial portfolio centers on HELIUM, USP — its most strategically important drugs approved in the last 15 years.

AIR LIQUIDE HEALTHCARE AMERICA CORP's Recent FDA Approvals

New NDA/BLA approvals for AIR LIQUIDE HEALTHCARE AMERICA CORP over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

AIR LIQUIDE HEALTHCARE AMERICA CORP's Therapeutic Areas

Disease areas where AIR LIQUIDE HEALTHCARE AMERICA CORP has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

AIR LIQUIDE HEALTHCARE AMERICA CORP Pipeline Snapshot

Active clinical trials for AIR LIQUIDE HEALTHCARE AMERICA CORP across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • HELIUM, USP leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Active trial monitoring
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling